First and only transgenic chicken platform engineered to express ultralong CDRH3 domains on a human antibody framework broadens therapeutic opportunities beyond conventional antibodies ...
OmniAb, Inc. (NASDAQ: OABI) today announced it will hold a virtual investor event to showcase the launch of OmniUltra ™ on Monday, December 15, 2025, beginning at 5:00 p.m. Eastern...
Issued on behalf of Aleen Inc. VANCOUVER – Baystreet.ca News Commentary – Healthcare's artificial intelligence transformation is accelerating at unprecedented speed, with AI spending hitting...
Agreement is focused on Omni dAb™ single domain technology OmniAb to receive revenue for discovery services as well as potential equity and royalties
Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today
OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in three investor conferences during the month of November. 2025...
OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and nine months ended September 30, 2025, after the close of the U.S. financial markets on Tuesday, November 4, 2025, and...
OmniAb, Inc. (NASDAQ: OABI) today announced that management will participate at the H.C. Wainwright 27 th Annual Global Investment Conference taking place September 8-10, 2025 at...
OmniAb, Inc. (NASDAQ: OABI) today announced it has entered into a definitive securities purchase agreement to issue and sell an aggregate of 21,254,106 shares of its common stock at a price of...
Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today